Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome
dc.authorid | Cengiz, Mustafa/0000-0002-3306-8058 | |
dc.authorid | Kulkarni, Anand/0000-0002-1240-1675 | |
dc.authorid | Harputluoglu, Muhsin Murat Muhip/0000-0002-9415-147X | |
dc.authorid | Ridruejo, Ezequiel/0000-0002-3321-0683 | |
dc.authorid | Androutsakos, Theodoros/0000-0003-2556-6230 | |
dc.authorid | Ebik, Berat/0000-0002-0012-2505 | |
dc.authorid | Güzelbulut, Fatih/0000-0003-4889-208X | |
dc.authorwosid | Duman, Serkan/ITV-8069-2023 | |
dc.authorwosid | Cengiz, Mustafa/ACL-5305-2022 | |
dc.authorwosid | Kulkarni, Anand/AFF-4945-2022 | |
dc.authorwosid | kumar, rahul/GZG-2171-2022 | |
dc.authorwosid | Harputluoglu, Muhsin Murat Muhip/ABI-3094-2020 | |
dc.authorwosid | Ridruejo, Ezequiel/H-7965-2019 | |
dc.authorwosid | Androutsakos, Theodoros/AAF-5209-2020 | |
dc.contributor.author | Efe, Cumali | |
dc.contributor.author | Kulkarni, Anand V. | |
dc.contributor.author | Terziroli Beretta-Piccoli, Benedetta | |
dc.contributor.author | Magro, Bianca | |
dc.contributor.author | Friedrich Staettermayer, Albert | |
dc.contributor.author | Cengiz, Mustafa | |
dc.contributor.author | Clayton-Chubb, Daniel | |
dc.date.accessioned | 2024-08-04T20:52:04Z | |
dc.date.available | 2024-08-04T20:52:04Z | |
dc.date.issued | 2022 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Background and Aims A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series. Approach and Results We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up. Conclusions SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient. | en_US |
dc.identifier.doi | 10.1002/hep.32572 | |
dc.identifier.endpage | 1586 | en_US |
dc.identifier.issn | 0270-9139 | |
dc.identifier.issn | 1527-3350 | |
dc.identifier.issue | 6 | en_US |
dc.identifier.pmid | 35567545 | en_US |
dc.identifier.scopus | 2-s2.0-85132426686 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 1576 | en_US |
dc.identifier.uri | https://doi.org/10.1002/hep.32572 | |
dc.identifier.uri | https://hdl.handle.net/11616/100730 | |
dc.identifier.volume | 76 | en_US |
dc.identifier.wos | WOS:000814517500001 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.ispartof | Hepatology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Idiopathic Autoimmune Hepatitis | en_US |
dc.subject | Disease | en_US |
dc.title | Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome | en_US |
dc.type | Article | en_US |